StockData

Fulcrum Therapeutics vs Keros Therapeutics

FULC and KROS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How FULC and KROS compare

Fulcrum Therapeutics is the larger company, worth 1.3 times as much as Keros Therapeutics ($286M against $224M).

Fulcrum Therapeutics scores higher on the StockData Score (8 against 7 for Keros Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFULCKROS
Size and price
Market cap$286M$224M
Share price$3.75$11.31
Change, 1 year−56.6%−34.5%
Change, 5 years−75.1%−79.8%
Beta (5Y)1.362.04
Employees5578
StockData Score
Total score8 (better)7
Valuation score11
Growth score00
Performance score11
Health score6 (better)5
Dividend score00
Valuation
P/S–15.4×
P/B0.9×0.9× (better)
FCF yield−23.1%−21.6% (better)
Growth
Revenue growth (TTM)–−93.7%
Net income growth (TTM)–−543%
EPS growth (TTM)–−1287%
Profitability
Operating margin–−698%
Net margin–−572%
FCF margin–−334%
Return on equity−32.4%−17.2% (better)
Return on invested capital−35.0% (better)−755%
Financial health
Debt / equity0.000.00
Current ratio31.35 (better)21.96
Altman Z-score10.37 (better)2.67
Piotroski F-score36 (better)
Dividends and buybacks
Buyback yield−1.5%–
Shareholder yield−1.5%0.00% (better)
Ownership
Held by institutions112%101%
Held by insiders34.7%53.3%
Insider net buying, 12 months−$57.5M−$453K (better)
Short interest, % of float12.9%11.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.